This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Zantrene shows impressive synergy with BRAF & MEK inhibitors in treating melanoma
28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use of Zantrene® (bisantrene dihydrochloride) in novel drug combinations for the treatment of both immunotherapy and…
-
Zantrene Improves Cancer Immunotherapy in a Mouse Model of Treatment Resistant Melanoma
22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from its preclinical melanoma research program (ASX announcement: 19 March 2021). The program’s objective was to explore the use of Zantrene® (bisantrene dihydrochloride) in novel drug combinations for the treatment of drug and immunotherapy resistant melanomas using cell and animal…
-
Novel preclinical data published in Cancer Research highlighting Zantrene’s potential in colorectal and pancreatic cancers
21 June 2022 – Race Oncology Limited (“Race”) is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or CS1) have been published in the prestigious scientific journal, Cancer Research, following their recent presentation at the American Association of Cancer…
-
Race Oncology Announces On-Market Share Buyback
09 June 2022 – Race Oncology Limited (“Race”) is pleased to announce the Board has approved an on-market share buyback for up to 4 million Race Oncology ordinary shares over the next 12 months. Race Oncology’s Board believes an on-market buyback is an efficient capital management option available to maximize shareholder value. All committed clinical…
-
Race Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe
08 June 2022 – Race Oncology Limited (“Race”) is pleased to announce it is expanding the FTO-targeted BISECT (RAC-006) clinical trial in extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS) to include five additional trial sites in Spain and Italy and has signed a new clinical support agreement with global Clinical Research Organisation,…
-
Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2
Race Oncology Limited (“Race”) is pleased to announce the dose escalation Phase 1b stage of the relapsed or refractory Acute Myeloid Leukaemia (R/R AML) trial running at the Chaim Sheba Medical Centre, Israel has successfully completed after the treatment of the first six patients.The six patients were heavily pre-treated and had received a median of…
-
Race Receives Governance Approval for Extramedullary AML & MDS Human Trial
Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic Syndrome (MDS). Human ethics approval for this trial has been granted (ASX…